PMID- 35116526
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 10
IP  - 5
DP  - 2021 May
TI  - RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or 
      advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and 
      meta-analysis.
PG  - 2044-2054
LID - 10.21037/tcr-20-3123 [doi]
AB  - BACKGROUND: With the advent of rituximab combined with cyclophosphamide, 
      doxorubicin, vincristine, and prednisolone (RCHOP) treatment has become 
      considered the appropriate chemotherapy treatment for aggressive or 
      advanced-stage indolent B-cell non-Hodgkins lymphoma (NHL). In recent years, 
      RCHOP-14 seems to have achieved better outcomes in patients with aggressive or 
      advanced-stage indolent B-cell NHL than RCHOP-21. METHODS: To verify the 
      befitting chemotherapy regimens for patients with B-cell NHL, we searched the 
      electronic databases for relevant English-language literature published in 
      January 2020. The primary outcomes were complete response (CR), progression-free 
      survival (PFS), overall survival (OS), and adverse events (AEs). Six eligible 
      Phase II and III randomized controlled clinical trials (RCTs) and two 
      high-quality observational comparative studies (OCSs) were extracted, with 5,565 
      patients with B-cell NHL involved in the evaluation. RESULTS: The analysis 
      demonstrated no significant difference in RCHOP-14 and RCHOP-21 CR rates [odds 
      ratio (OR) =0.98, 95% CI: 0.77-1.24, P=0.85]. Compared with RCHOP-21, the merged 
      hazard ratio (HR) after treatment with RCHOP-14 for PFS and OS was 0.94 (95% CI: 
      0.84-1.06, P=0.32) and 0.91 (95% CI: 0.83-1.01, P=0.08), respectively. A subgroup 
      analysis based on the international prognostic index (IPI) score showed that both 
      chemotherapy regimens were applicable in B-cell NHL patients with different 
      prognoses. The frequency of toxic side-effects was similar between schemes. 
      CONCLUSIONS: The data presented suggest that the efficacy and safety of both 
      regimens are comparable and that RCHOP-14 remains a viable plan in patients with 
      B-cell NHL who prefer a shorter therapy course.
CI  - 2021 Translational Cancer Research. All rights reserved.
FAU - He, Yue
AU  - He Y
AD  - Department of Hematology, the 1st Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Tao, Wenqiang
AU  - Tao W
AD  - Department of ICU, the 1st Affiliated Hospital of Nanchang University, Nanchang, 
      China.
FAU - Ji, Dexiang
AU  - Ji D
AD  - Department of Hematology, the 1st Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Lu, Wei
AU  - Lu W
AD  - Department of Hematology, the 1st Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Xiong, Yu
AU  - Xiong Y
AD  - Department of Emergency, the 1st Hospital of Nanchang City, Nanchang, China.
FAU - Chen, Guoan
AU  - Chen G
AD  - Department of Hematology, the 1st Affiliated Hospital of Nanchang University, 
      Nanchang, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798725
OTO - NOTNLM
OT  - Aggressive
OT  - B-cell lymphoma
OT  - a systematic review
OT  - indolent
OT  - rituximab combined with cyclophosphamide, doxorubicin, vincristine, and 
      prednisolone (RCHOP)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-20-3123). The authors have no 
      conflicts of interest to declare.
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2021/05/01
CRDT- 2022/02/04 05:49
PHST- 2020/10/22 00:00 [received]
PHST- 2021/03/05 00:00 [accepted]
PHST- 2022/02/04 05:49 [entrez]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2021/05/01 00:00 [pmc-release]
AID - tcr-10-05-2044 [pii]
AID - 10.21037/tcr-20-3123 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2021 May;10(5):2044-2054. doi: 10.21037/tcr-20-3123.